REPLIGEN CORP (RGEN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
72/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinRGEN / S&P 15.80% / 15.20% |
WinRGEN / S&P 16.49% / 15.00% |
LoseRGEN / S&P -380.77% / 50.40% |
| 2026-Q11/3 |
LoseRGEN / S&P -28.10% / -4.33% |
WinRGEN / S&P 17.36% / 11.30% |
LoseRGEN / S&P -314.29% / 27.70% |
| 2025-Q42/3 |
WinRGEN / S&P 22.59% / 2.65% |
WinRGEN / S&P 16.36% / 9.00% |
LoseRGEN / S&P -284.78% / 13.40% |
| 2025-Q31/3 |
LoseRGEN / S&P 7.47% / 8.12% |
WinRGEN / S&P 11.74% / 4.61% |
LoseRGEN / S&P -107.69% / 13.45% |
| 2025-Q21/3 |
LoseRGEN / S&P -2.25% / 10.94% |
WinRGEN / S&P 8.73% / 4.83% |
LoseRGEN / S&P -244.44% / 10.63% |
| 2025-Q10/3 |
LoseRGEN / S&P -11.60% / -4.27% |
LoseRGEN / S&P 4.88% / 4.98% |
LoseRGEN / S&P -197.67% / 10.57% |
| 2024-Q40/3 |
LoseRGEN / S&P -3.28% / 2.41% |
LoseRGEN / S&P -2.34% / 5.25% |
LoseRGEN / S&P -152.27% / 6.15% |
| 2024-Q31/3 |
WinRGEN / S&P 18.05% / 5.89% |
LoseRGEN / S&P -5.42% / 5.89% |
LoseRGEN / S&P -106.47% / 6.11% |
| 2024-Q20/3 |
LoseRGEN / S&P -31.46% / 4.28% |
LoseRGEN / S&P -15.01% / 5.38% |
LoseRGEN / S&P -92.56% / 5.12% |
| 2024-Q10/3 |
LoseRGEN / S&P 2.29% / 10.56% |
LoseRGEN / S&P -20.27% / 5.71% |
LoseRGEN / S&P -85.42% / 5.59% |
| 2023-Q41/3 |
WinRGEN / S&P 13.07% / 11.69% |
LoseRGEN / S&P -18.95% / 6.81% |
LoseRGEN / S&P -72.92% / 7.78% |
| 2023-Q31/3 |
WinRGEN / S&P 12.41% / -3.27% |
LoseRGEN / S&P -16.41% / 7.52% |
LoseRGEN / S&P -30.69% / -5.03% |
| 2023-Q20/3 |
LoseRGEN / S&P -15.98% / 8.74% |
LoseRGEN / S&P -6.35% / 9.50% |
LoseRGEN / S&P -12.64% / -8.57% |
| 2023-Q11/3 |
LoseRGEN / S&P -0.56% / 7.50% |
LoseRGEN / S&P 5.95% / 10.77% |
WinRGEN / S&P 16.60% / -15.69% |
| 2022-Q42/3 |
LoseRGEN / S&P -9.51% / 7.56% |
WinRGEN / S&P 19.54% / 11.88% |
WinRGEN / S&P 45.09% / -17.99% |
| 2022-Q33/3 |
WinRGEN / S&P 15.22% / -4.88% |
WinRGEN / S&P 35.20% / 13.47% |
WinRGEN / S&P 38.10% / -1.41% |
| 2022-Q23/3 |
WinRGEN / S&P -13.66% / -16.10% |
WinRGEN / S&P 53.15% / 13.71% |
WinRGEN / S&P 54.75% / 11.04% |
| 2022-Q12/3 |
LoseRGEN / S&P -28.98% / -4.60% |
WinRGEN / S&P 69.53% / 15.97% |
WinRGEN / S&P 74.48% / 42.23% |
| 2021-Q42/3 |
LoseRGEN / S&P -8.36% / 11.03% |
WinRGEN / S&P 83.08% / 15.00% |
WinRGEN / S&P 101.80% / 96.40% |
| 2021-Q33/3 |
WinRGEN / S&P 44.77% / 0.58% |
WinRGEN / S&P 81.19% / 10.77% |
WinRGEN / S&P 156.10% / 69.42% |
| 2021-Q22/3 |
LoseRGEN / S&P 2.68% / 8.55% |
WinRGEN / S&P 68.12% / 6.58% |
WinRGEN / S&P 208.62% / 51.81% |
| 2021-Q12/3 |
LoseRGEN / S&P 1.45% / 6.17% |
WinRGEN / S&P 51.56% / -1.06% |
WinRGEN / S&P 222.22% / 7.39% |
| 2020-Q43/3 |
WinRGEN / S&P 29.88% / 12.15% |
WinRGEN / S&P 35.53% / -3.72% |
WinRGEN / S&P 152.27% / -33.42% |
| 2020-Q33/3 |
WinRGEN / S&P 19.36% / 8.93% |
WinRGEN / S&P 29.43% / -2.04% |
WinRGEN / S&P 64.00% / -27.10% |
| 2020-Q23/3 |
WinRGEN / S&P 28.04% / 20.54% |
WinRGEN / S&P 29.93% / -0.46% |
WinRGEN / S&P 1.75% / -27.11% |
| 2020-Q13/3 |
WinRGEN / S&P 4.37% / -19.60% |
WinRGEN / S&P 36.15% / 3.47% |
WinRGEN / S&P -2.17% / -14.75% |
| 2019-Q43/3 |
WinRGEN / S&P 20.62% / 9.07% |
WinRGEN / S&P 39.28% / 5.36% |
WinRGEN / S&P 18.92% / 2.99% |
| 2019-Q31/3 |
LoseRGEN / S&P -10.77% / 1.70% |
WinRGEN / S&P 37.57% / 5.02% |
LoseRGEN / S&P -5.66% / 0.21% |
| 2019-Q22/3 |
WinRGEN / S&P 45.48% / 4.30% |
WinRGEN / S&P 36.34% / 6.64% |
LoseRGEN / S&P 5.56% / 8.65% |
| 2019-Q11/3 |
LoseRGEN / S&P 12.02% / 13.65% |
WinRGEN / S&P 34.96% / 8.12% |
LoseRGEN / S&P -36.11% / 14.29% |
| 2018-Q42/3 |
WinRGEN / S&P -4.90% / -13.52% |
WinRGEN / S&P 37.38% / 9.05% |
LoseRGEN / S&P -49.32% / 18.23% |
| 2018-Q32/3 |
WinRGEN / S&P 17.90% / 7.71% |
WinRGEN / S&P 46.70% / 10.21% |
LoseRGEN / S&P -8.62% / 19.06% |
| 2018-Q22/3 |
WinRGEN / S&P 30.02% / 3.43% |
WinRGEN / S&P 50.68% / 9.03% |
LoseRGEN / S&P 8.00% / 14.46% |
| 2018-Q13/3 |
WinRGEN / S&P -0.28% / -0.76% |
WinRGEN / S&P 41.30% / 7.68% |
WinRGEN / S&P 94.59% / 12.46% |
| 2017-Q42/3 |
LoseRGEN / S&P -5.32% / 6.64% |
WinRGEN / S&P 35.10% / 7.03% |
WinRGEN / S&P 121.21% / 13.82% |
| 2017-Q32/3 |
LoseRGEN / S&P -7.53% / 4.48% |
WinRGEN / S&P 24.74% / 5.68% |
WinRGEN / S&P 190.00% / 17.57% |
| 2017-Q23/3 |
WinRGEN / S&P 17.73% / 3.09% |
WinRGEN / S&P 18.63% / 4.83% |
WinRGEN / S&P 100.00% / 17.74% |
| 2017-Q13/3 |
WinRGEN / S&P 14.21% / 6.07% |
WinRGEN / S&P 25.31% / 3.67% |
WinRGEN / S&P 48.00% / 13.32% |
| 2016-Q42/3 |
LoseRGEN / S&P 2.09% / 3.82% |
WinRGEN / S&P 25.14% / 2.09% |
WinRGEN / S&P 13.79% / 7.05% |
| 2016-Q32/3 |
WinRGEN / S&P 10.34% / 3.85% |
WinRGEN / S&P 27.92% / 0.20% |
LoseRGEN / S&P -25.93% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 48.81% | 20.78% |
| Annualized return | 48.81% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -36.32% | 83.14% |
| Annualized return | -8.63% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | RGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 486.44% | 319.30% |
| Annualized return | 19.35% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |